NASDAQ:HOLX - Hologic Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $41.94 -0.90 (-2.10 %) (As of 12/14/2018 04:00 PM ET)Previous Close$41.94Today's Range$41.84 - $42.7152-Week Range$35.10 - $45.17Volume1.75 million shsAverage Volume1.99 million shsMarket Capitalization$12.39 billionP/E Ratio18.81Dividend YieldN/ABeta0.69 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Hologic, Inc., a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health. The company offers Aptima molecular diagnostic assays, target capture/nucleic acid extraction technology, transcription-mediated amplification technology, hybridization protection and dual kinetic assay technologies, instrumentation, Invader chemistry platform, ThinPrep system, and rapid fetal fibronectin test products. It also provides breast imaging and analytics products, such as 2D and 3D mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, and breast biopsy and biopsy site markers, as well as localization, specimen radiology, ultrasound, and connectivity solutions. In addition, the company offers Selenia Dimensions and 3Dimensions gantries for performing 2D and tomosynthesis image acquisition and display; C-View and Intelligent 2D software products; SecurView Workstations; computer aided detection systems; and stereotactic breast biopsy systems. Further, it provides SculpSure, PicoSure, and MonaLisa Touch aesthetic treatment systems; TempSure, a radio frequency energy sourced platform; and MedLite and other products, and system components for medical aesthetics. Additionally, the company offers NovaSure, an endometrial ablation system to treat women suffering from abnormal uterine bleeding; MyoSure surgical products for removal of fibroids, and uterine polyps and other pathology; and Horizon DXA System and Fluoroscan Insight FD skeletal health products. It sells its products through direct sales and service forces, and a network of independent distributors and sales representatives. The company was founded in 1985 and is headquartered in Marlborough, Massachusetts. Receive HOLX News and Ratings via Email Sign-up to receive the latest news and ratings for HOLX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry X-ray apparatus & tubes Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNASDAQ:HOLX Previous Symbol CUSIP43644010 Webwww.hologic.com Phone508-263-2900 Debt Debt-to-Equity Ratio1.12 Current Ratio1.23 Quick Ratio0.95 Price-To-Earnings Trailing P/E Ratio18.81 Forward P/E Ratio17.48 P/E Growth1.98 Sales & Book Value Annual Sales$3.22 billion Price / Sales3.77 Cash Flow$3.9529 per share Price / Cash Flow10.61 Book Value$8.93 per share Price / Book4.70 Profitability EPS (Most Recent Fiscal Year)$2.23 Net Income$-111,300,000.00 Net Margins-3.46% Return on Equity23.52% Return on Assets8.36% Miscellaneous Employees6,252 Outstanding Shares289,210,000Market Cap$12.39 billion OptionableOptionable Hologic (NASDAQ:HOLX) Frequently Asked Questions What is Hologic's stock symbol? Hologic trades on the NASDAQ under the ticker symbol "HOLX." How were Hologic's earnings last quarter? Hologic, Inc. (NASDAQ:HOLX) released its earnings results on Wednesday, November, 7th. The medical equipment provider reported $0.58 earnings per share for the quarter, missing analysts' consensus estimates of $0.59 by $0.01. The medical equipment provider had revenue of $813.50 million for the quarter, compared to analysts' expectations of $808.63 million. Hologic had a negative net margin of 3.46% and a positive return on equity of 23.52%. The firm's quarterly revenue was up 1.3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.50 EPS. View Hologic's Earnings History. When is Hologic's next earnings date? Hologic is scheduled to release their next quarterly earnings announcement on Thursday, February 14th 2019. View Earnings Estimates for Hologic. What guidance has Hologic issued on next quarter's earnings? Hologic issued an update on its FY19 earnings guidance on Wednesday, November, 7th. The company provided earnings per share (EPS) guidance of $2.38-2.42 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.42. The company issued revenue guidance of $3.29-3.34 billion, compared to the consensus revenue estimate of $3.32 billion.Hologic also updated its FY 2019 guidance to $2.38-2.42 EPS. What price target have analysts set for HOLX? 16 brokers have issued 12 month price targets for Hologic's shares. Their predictions range from $40.00 to $50.00. On average, they expect Hologic's share price to reach $44.6250 in the next twelve months. This suggests a possible upside of 6.4% from the stock's current price. View Analyst Price Targets for Hologic. What is the consensus analysts' recommendation for Hologic? 16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hologic in the last year. There are currently 9 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Hologic. What are Wall Street analysts saying about Hologic stock? Here are some recent quotes from research analysts about Hologic stock: 1. According to Zacks Investment Research, "Hologic exited the fiscal 2018 on a mixed note with fourth-quarter earnings missing the Zacks Consensus Estimate and revenues beating the same. Strong international performance and improvement in Surgical and Cynosure businesses are encouraging. Backed by a portfolio of differentiated products, the company’s Breast Health business has been going strong. We are upbeat about the company making the Open Access functionality available for its Panther Fusion system. Also, the receipt of CE Mark for its Panther FusionBordetella assay buoys optimism. Hologic has outperformed its industry in the past three months. However, tough year-ago comparison along with sluggish Diagnostics sales in the reported quarter hampered Hologic’s overall performance. Also, the blood screening divestiture is likely to impede growth." (11/13/2018) 2. Canaccord Genuity analysts commented, "We believe the stock is up today because HOLX (1) removed uncertainty regarding its 2019 guide and (2) announced agreements to renew with LH and DGX, which we think alleviates a modest overhang on the stock. HOLX’s top line guide of ~2-3.5% growth is not enough for us to get excited about. We look for signs of faster growth and progress mitigating margin drags and reiterate our HOLD. We raise our PT from $41 to $43, as we roll forward a 16.5x multiple on our new ’20E Adj. EPS of $2.60. Alleviates lab contract overhang. HOLX has agreed to deals with large lab customers (LH & DGX), a positive outcome to a modest overhang on the stock. One deal is a multi- year" extension of its supply contract while the other provides instruments and tests. While we view these deals favorably, we believe HOLX likely made price concessions to do the deals." (11/8/2018) 3. Needham & Company LLC analysts commented, "HOLX is acquiring Focal Therapeutics (private) for $125M in cash. HOLX expects the acquisition to close in and be neutral to HOLX’s FY19 adjusted EPS. Focal Therapeutics’s BioZorb implant advances post- operation tumor removal area identification. We view this transaction as an affordable way to strengthen HOLX’s Breast Health business and it appears to be complementary to HOLX’s recent Faxitron acquisition. We reiterate our Buy rating." (9/27/2018) 4. BTIG Research analysts commented, "Raising PT to $47 from $44 After a tough F2Q, all eyes were on HOLX’s Cynosure Aesthetics business going into this F3Q. CYNO sales of $91.7M exceeded the Street’s bar of ~$88M and we think HOLX shares may enjoy a small relief rally Wednesday. We think investors will also want to see long-term growth here. The company’s core businesses remained solid, with a nice revenue beat in Breast Health and strong Blood Screening sales. We were also encouraged by what seemed like stabilization in the GYN Surgical division. Beyond these results, HOLX picked up and announced a new CFO (internal promotion) as the prior CFO moves on to Agilent. In our view, revenue guidance for F4Q set below Street estimates may have been slightly conservative, but we view this as a positive quarter overall for HOLX. We raise our PT to $47 from $44 previously, now based on 18x our 12-24 mo. adj. EPS estimate." (8/2/2018) Has Hologic been receiving favorable news coverage? News coverage about HOLX stock has trended somewhat positive on Saturday, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Hologic earned a news impact score of 1.2 on InfoTrie's scale. They also assigned media coverage about the medical equipment provider a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the company's share price in the next several days. Are investors shorting Hologic? Hologic saw a increase in short interest during the month of November. As of November 30th, there was short interest totalling 10,579,846 shares, an increase of 30.5% from the November 15th total of 8,107,826 shares. Based on an average daily trading volume, of 2,369,507 shares, the days-to-cover ratio is presently 4.5 days. Approximately 3.7% of the company's shares are sold short. View Hologic's Current Options Chain. Who are some of Hologic's key competitors? Some companies that are related to Hologic include Illumina (ILMN), Celgene (CELG), HCA Healthcare (HCA), Vertex Pharmaceuticals (VRTX), Zoetis (ZTS), Humana (HUM), Regeneron Pharmaceuticals (REGN), Baxter International (BAX), Edwards Lifesciences (EW), Actelion (ALIOF), ASTELLAS PHARMA/ADR (ALPMY), ESSILOR Intl S/S (ESLOY), Centene (CNC), Takeda Pharmaceutical (TKPYY) and Eisai (ESALY). Who are Hologic's key executives? Hologic's management team includes the folowing people: Mr. Stephen P. MacMillan, Chairman, CEO & Pres (Age 54)Mr. John M. Griffin, Gen. Counsel (Age 57)Mr. Peter J. Valenti III, Division Pres of Breast & Skeletal Health Solutions (Age 55)Mr. Eric B. Compton, Consultant (Age 53)Dr. Jay A. Stein, Co-Founder, Chairman Emeritus, CTO & Sr. VP (Age 75) Who are Hologic's major shareholders? Hologic's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Vanguard Group Inc (9.77%), Capital World Investors (10.22%), BlackRock Inc. (6.90%), Capital Research Global Investors (5.50%), Victory Capital Management Inc. (1.42%) and Pictet Asset Management Ltd. (1.31%). Company insiders that own Hologic stock include Allison P Bebo, Benjamin Jordan Cohn, Charles J Dockendorff, Christiana Stamoulis, Elaine Ullian, Karleen Marie Oberton, Lawrence M Levy, Namal Nawana, Peter J Valenti III and Sally Crawford. View Institutional Ownership Trends for Hologic. Which institutional investors are selling Hologic stock? HOLX stock was sold by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Point72 Asset Management L.P., Victory Capital Management Inc., Wells Fargo & Company MN, First Trust Advisors LP, Mitsubishi UFJ Trust & Banking Corp, United Services Automobile Association and American Capital Management Inc.. Company insiders that have sold Hologic company stock in the last year include Allison P Bebo, Benjamin Jordan Cohn, Christiana Stamoulis, Karleen Marie Oberton, Peter J Valenti III and Sally Crawford. View Insider Buying and Selling for Hologic. Which institutional investors are buying Hologic stock? HOLX stock was acquired by a variety of institutional investors in the last quarter, including Capital International Investors, The Manufacturers Life Insurance Company, Man Group plc, Capital World Investors, Vanguard Group Inc, JPMorgan Chase & Co., JPMorgan Chase & Co. and Korea Investment CORP. Company insiders that have bought Hologic stock in the last two years include Charles J Dockendorff and Namal Nawana. View Insider Buying and Selling for Hologic. How do I buy shares of Hologic? Shares of HOLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Hologic's stock price today? One share of HOLX stock can currently be purchased for approximately $41.94. How big of a company is Hologic? Hologic has a market capitalization of $12.39 billion and generates $3.22 billion in revenue each year. The medical equipment provider earns $-111,300,000.00 in net income (profit) each year or $2.23 on an earnings per share basis. Hologic employs 6,252 workers across the globe. What is Hologic's official website? The official website for Hologic is http://www.hologic.com. How can I contact Hologic? Hologic's mailing address is 250 CAMPUS DRIVE, MARLBOROUGH MA, 01752. The medical equipment provider can be reached via phone at 508-263-2900 or via email at [email protected] MarketBeat Community Rating for Hologic (NASDAQ HOLX)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 643 (Vote Outperform)Underperform Votes: 475 (Vote Underperform)Total Votes: 1,118MarketBeat's community ratings are surveys of what our community members think about Hologic and other stocks. Vote "Outperform" if you believe HOLX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HOLX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/15/2018 by MarketBeat.com StaffFeatured Article: How does a 12b-1 fee affect fund performance?